Certolizumab pegol improves HRQoL in patients with Crohn's disease: Data from PRECiSE 2

被引：0
|
作者：
Feagan, B.
Keininger, D.
Coteur, G.
Schreiber, S.
机构：
[1] Robarts Res Inst, London, ON N6A 5C1, Canada
[2] Univ Kiel, Kiel, Germany
[3] SGS Life Sci Serv, Mechelen, Belgium
来源：
INFLAMMATORY BOWEL DISEASES | 2007年 / 13卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：661 / 662
页数：2
相关论文
共 50 条
  • [1] Treatment with certolizumab pegol 400 mg improves work productivity and daily activities in patients with Crohn's disease: PRECISE 2 data
    Brown, Martin C. J.
    Feagan, Brian G.
    Gerlier, Laetitia C.
    Schreiber, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S403 - S403
  • [2] Confirmed benefits of work productivity and daily activities of certolizumab pegol in Crohn's disease patients: Data from PRECISE
    Feagan, Brian G.
    Sandborn, William J.
    Brown, Martin
    Brabant, Yves
    Gerlier, Laetitia
    GASTROENTEROLOGY, 2007, 132 (04) : A507 - A508
  • [3] Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study
    Sandborn, William J.
    Schreiber, Stefan
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Bloomfield, Ralph
    Lichtenstein, Gary R.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (08) : 696 - 702
  • [4] Certolizumab pegol in Crohn's disease
    Blick, Stephanie K. A.
    Curran, Monique P.
    BIODRUGS, 2007, 21 (03) : 195 - 201
  • [5] Predictors of response in patients with active Crohn's disease treated with certolizumab pegol: A multiple regression analysis of PRECISE 2 data
    Hanauer, Stephen B.
    Schreiber, Stefan
    Thomsen, Ole O.
    Lichtenstein, Gary R.
    Bloomfield, Ralph
    Sandborn, William J.
    GASTROENTEROLOGY, 2008, 134 (04) : A489 - A490
  • [6] CERTOLIZUMAB PEGOL IN CROHN'S DISEASE
    Patel, V. K.
    Ghosh, S.
    DRUGS OF TODAY, 2008, 44 (11) : 837 - 844
  • [7] Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study
    Lee, Scott D.
    Rubin, David T.
    Sandborn, William J.
    Randall, Charles
    Younes, Ziad
    Schreiber, Stefan
    Schwartz, David A.
    Burakoff, Robert
    Binion, David
    Dassopoulos, Themos
    Arsenescu, Razvan
    Gutierrez, Alexandra
    Scherl, Ellen
    Kayhan, Cem
    Hasan, Iram
    Kosutic, Gordana
    Spearman, Marshall
    Sen, David
    Coarse, Jason
    Hanauer, Stephen
    INFLAMMATORY BOWEL DISEASES, 2016, 22 (08) : 1870 - 1880
  • [8] Fecal Calprotectin Concentration and Clinical Response to Certolizumab Pegol in Patients with Active Crohn's Disease: Results from PRECiSE 2
    Sandborn, William
    Pierre-Louis, Bosny
    Ullman, Thomas
    Binion, David
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S453 - S453
  • [9] Fecal calprotectin concentration and clinical response to certolizumab pegol in patients with active Crohn's disease: results from PRECiSE 2
    Sandborn, William J.
    Pierre-Louis, Bosny
    Ullman, Thomas A.
    Binion, David G.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S24 - S25
  • [10] Efficacy of Certolizumab Pegol Therapy in Patients With Crohn's Disease
    Shafran, Ira
    Al-Maani, Sayel
    Burgunder, Patricia
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S451 - S451
12345